These shifts in prescribing, regarding choice of substance and brand, could partially be explained by the recommendations issued by the Drug and Therapeutics Committee in Region Stockholm (Kloka listan) [62] and the year of market introductions of Ozempic and Rybelsus
Each woman taking GLP-1 drugs was matched with a woman not taking the drugs, based on factors such as age, race, ethnicity, BMI, breast density, and diabetes status
* Lutein See a healthy future for your eyes with lutein
Such monitoring may increase the risk of unnecessary procedures, due to low test specificity for serum calcitonin and a high background incidence of thyroid disease
But if the peptide degraded during transit, potency is reduced and degradation products may be present
The same pattern holds for tirzepatide